Diffuse midline glioma of the brainstem: genetic features, complications and treatment prospects

Cover Page

Cite item

Full Text

Abstract

Diffuse midline glioma of the brain is a rare but very aggressive and resistant glial tumor. This pathology is characterized by impossibility of radical surgical treatment, radioresistance, resistance to drug treatment, high morbidity in children, low quality of life of the patients, frequent complications in the form of neurologic deficit, and unfavorable prognosis. The absence of effective treatment scheme for diffuse midline glioma requires identification of other methods (oncolytic virus therapy, immunotherapy) but there is not enough data on this topic leading to the necessity of its further investigation.

About the authors

A. M. Kryanev

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department

Email: fake@neicon.ru
ORCID iD: 0000-0002-1505-2976

5 2nd Botkinsky Proezd, Moscow 125284

Russian Federation

I. D. Rozanov

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department

Author for correspondence.
Email: oncolog.rozanov@yandex.ru
ORCID iD: 0000-0003-0626-5272

Ivan D. Rozanov.

5 2nd Botkinsky Proezd, Moscow 125284

Russian Federation

S. S. Lebedev

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-5366-1281

5 2nd Botkinsky Proezd, Moscow 125284; Bld. 1, 2 / 1 Barricadnaya St., Moscow 125993

Russian Federation

D. N. Grekov

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-8391-1210

5 2nd Botkinsky Proezd, Moscow 125284; Bld. 1, 2 / 1 Barricadnaya St., Moscow 125993

Russian Federation

K. S. Titov

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department; Peoples' Friendship University of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-4460-9136

5 2nd Botkinsky Proezd, Moscow 125284; 6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

T. A. Yakusheva

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department; Peoples' Friendship University of Russia

Email: fake@neicon.ru
ORCID iD: 0009-0005-2715-3933

5 2nd Botkinsky Proezd, Moscow 125284; 6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

M. Kh. Salpagarov

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department

Email: fake@neicon.ru
ORCID iD: 0009-0002-1562-8944

5 2nd Botkinsky Proezd, Moscow 125284

Russian Federation

References

  1. Hargrave D., Bartels U., Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006;7(3):241-8. doi: 10.1016/S1470-2045(06)70615-5
  2. Hennika T., Becher O.J. Diffuse Intrinsic pontine glioma: time for cautious optimism. J Child Neurol 2016;31(12):1377—85. doi: 10.1177/0883073815601495
  3. Schroeder K.M., Hoeman C.M., Becher O.J. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res 2014;75(1-2):205-9. doi: 10.1038/pr.2013.194
  4. Tinkle C.L., Duncan E.C., Doubrovin M. et al. Evaluation of 11C-methionine PET and anatomic MRI associations in diffuse intrinsic pontine glioma. J Nucl Med 2019;60(3):312-9. doi: 10.2967/jnumed.118.212514
  5. Kossatz S., Carney B., Schweitzer M. et al. Biomarker-based PET imaging of diffuse Intrinsic pontine glioma in mouse models. Cancer Res 2017;77(8):2112-23. doi: 10.1158/0008-5472.CAN-16-2850
  6. Grimm S.A., Chamberlain M.C. Brainstem glioma: a review. Curr Neurol Neurosci Rep 2013;13(5):346. doi: 10.1007/s11910-013-0346-3
  7. Pollack I.F., Agnihotri S., Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr 2019;23(3):261-73. doi: 10.3171/2018.10.PEDS18377
  8. Liu I., Jiang L., Samuelsson E.R. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet 2022;54(12):1881-94. doi: 10.1038/s41588-022-01236-3
  9. Gwak H.-S., Park H.J. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol 2017;120:111-9. doi: 10.1016/j.critrevonc.2017.10.013
  10. Hoffman L.M., Veldhuijzen van Zanten S.E.M., Colditz N. et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol 2018;36(19):1963-72. doi: 10.1200/JCO.2017.75.9308
  11. Miguel Llordes G., Medina Perez V.M., Curto Simon B. et al. Epidemiology, diagnostic strategies, and therapeutic advances in diffuse midline glioma. J Clin Med 2023;12(16):5261. doi: 10.3390/jcm12165261
  12. Gerstner E.R. MRI and PET: noninvasive tools to probe the biology of diffuse intrinsic pontine glioma. J Nucl Med 2017;8(8):1262-3. doi: 10.2967/jnumed.117.192526
  13. Perrone M.G., Ruggiero A., Centonze A. et al. Diffuse intrinsic pontine glioma (DIPG): breakthrough and clinical perspective. Curr Med Chem 2021;28(17):3287-317. doi: 10.2174/0929867327666200806110206
  14. Robison N.J., Kieran M.W. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol 2014;119(1):7-15. doi: 10.1007/s11060-014-1448-8
  15. Mackay A., Burford A., Carvalho D. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520-37.e5. doi: 10.1016/j.ccell.2017.08.017
  16. Yu J.-R., LeRoy G., Bready D. et al. The H3K36me2 writer-reader dependency in H3K27M-DIPG Sci Adv 2021;7(9):eabg7444. doi: 10.1126/sciadv.abg7444
  17. Buczkowicz P., Hoeman C., Rakopoulos P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014;46(5):451-6. doi: 10.1038/ng.2936
  18. Majzner R.G., Ramakrishna S., Yeom K.W. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022;603(7903):934-41. doi: 10.1038/s41586-022-04489-4
  19. Kurdi N., Mokanszki A., Mehes G., Bedekovics J. Histone H3 K27 alterations in central nervous system tumours: challenges and alternative diagnostic approaches. Mol Cell Probes 2022;66:101876. doi: 10.1016/j.mcp.2022.101876
  20. Wu G., Diaz A.K., Paugh B.S. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46(5):444-50. doi: 10.1038/ng.2938
  21. Chi A.S., Tarapore R.S., Hall M.D. et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 2019;145(1):97-105. doi: 10.1007/s11060-019-03271-3
  22. Carai A., Marcus H.J., Tisdall M., Aquilina K. Robot-assisted stereotactic biopsy of diffuse Intrinsic pontine glioma: a single-center experience.World Neurosurg 2017;101:584-8. doi: 10.1016/j.wneu.2017.02.088
  23. Morana G., Tortora D., Bottoni G. et al. Correlation of multimodal 18F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas. Theranostics 2020;10(26):11881-91. doi: 10.7150/thno.50598
  24. Wang Z.J., Rao L., Bhambhani K. et al. Diffuse intrinsic pontine glioma biopsy: a single institution experience. Pediatr Blood Cancer 2015;62(1):163-5. doi: 10.1002/pbc.25224
  25. Rashed W.M., Maher E., Adel M. et al. Pediatric diffuse intrinsic pontine glioma: where do we stand? Cancer Metastasis Rev 2019;38(4):759-70. doi: 10.1007/s10555-019-09824-2
  26. Baker S.J., Ellison D.W., Gutmann D.H. Pediatric gliomas as neurodevelopmental disorders. Glia 2016;64(6):879-95. doi: 10.1002/glia.22945
  27. Hu X., Fang Y., Hui X. et al. Radiotherapy for diffuse brainstem glioma in children and young adults. Cochrane Database Syst Rev 2016;2016(6):CD010439. doi: 10.1002/14651858.CD010439.pub2
  28. Kim H.J., Suh C.-O. Radiotherapy for diffuse intrinsic pontine glioma: insufficient but indispensable. Brain Tumor Res Treat 2023;11(2):79-85. doi: 10.14791/btrt.2022.0041
  29. Reyes-Botero G., Laigle-Donadey F., Mokhtari K. et al. Temozolomide after radiotherapy in recurrent „low grade“ diffuse brainstem glioma in adults. J Neurooncol 2014;120(3):581-6. doi: 10.1007/s11060-014-1589-9
  30. Rizzo D., Scalzone M., Ruggiero A. et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother 2015;27(2):106-10. doi: 10.1179/1973947814Y.0000000228
  31. Wierzbicki K., Ravi K., Franson A. et al. Targeting and therapeutic monitoring of H3K27M-mutant glioma. Curr Oncol Rep 2020;22(2):19. doi: 10.1007/s11912-020-0877-0
  32. Rozanov I.D., Lebedev S.S., Grekov et al. Drug therapy of glioblastoma of the brain. Onkologiya. Zhurnal im. P.A. Gercena = Oncology. P.A. Herzen Journal 2023;12(5): 65-70. (In Russ.). doi: 10.17116/onkolog20231205165
  33. Warren K.E. Beyond the blood: brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Front Oncol 2018;8:239. doi: 10.3389/fonc.2018.00239
  34. Carvalho D.M., Richardson P.J., Olaciregui N. et al. Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discov 2022;12(2):416-31. doi: 10.1158/2159-8290.CD-20-1201
  35. Gardner S.L., Tarapore R.S., Allen J. et al. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neurooncol Adv 2022;4(1):vdac143. doi: 10.1093/noajnl/vdac143
  36. Flannery P.C., DeSisto J.A., Amani V. et al. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 2018;39(2):455-64. doi: 10.3892/or.2017.6122
  37. Gállego Pérez-Larraya J., Garcia-Moure M., Labiano S.P. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med 2022;386(26):2471-81. doi: 10.1056/NEJMoa2202028
  38. Josupeit R., Bender S., Kern S. et al. Pediatric and Adult high-grade glioma stem cell culture models are permissive to lytic infection with parvovirus H-1. Viruses 2016;8(5):138. doi: 10.3390/v8050138
  39. Chastkofsky M.I., Pituch K.C., Katagi H. et al. Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma. Clin Cancer Res 2021;27(6):1766-77. doi: 10.1158/1078-0432.CCR-20-1499

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.